secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001558370-23-008380
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris posts Q1 net loss of $28.2M; delays PsA and AD trial data timelines
---------------------------------------------------------------------------

- Net loss widened to $28.2M from $18.8M YoY; revenue rose to $2.5M on higher licensing royalties.
- Cash, cash equivalents and marketable securities $204.4M; ATM raised $26.7M net in April, extending runway through end-2025.
- Zunsemetinib RA Phase 2b data guided to Q4 2023; PsA Phase 2a data delayed to H1 2024 (from YE 2023) due to slow European enrollment.
- ATI-1777 AD Phase 2b data now expected H2 2023 (from mid-year) after protocol expansion to include milder disease.
- ATI-2138 MAD data on track for H2 2023; ulcerative colitis selected as first development target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023008380/0001558370-23-008380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023008380/acrs-20230508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer